RecruitingNCT00935090

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)

Sponsor

Barbara Ann Karmanos Cancer Institute

Start Date

Sep 1, 2009

Study Type

INTERVENTIONAL

Conditions

Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Leukemia Myelodysplastic Syndromes Lymphoproliferative Disorder Chronic Myeloproliferative Disorders Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic/Myeloproliferative Neoplasms Brain and Central Nervous System Tumors

Summary

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Eligibility

Min Age: 18 YearsMax Age: 120 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying a special imaging scan (called a PET scan) that uses a radioactive tracer to help doctors see cancer more clearly in the body. You may be eligible if: you have a confirmed cancer diagnosis (either a solid tumor or a blood cancer), or you are waiting for a biopsy or surgery to find out if a suspicious mass is cancer; you are able to lie still in the scanner; and your body size fits the scanner. You may NOT be eligible if: you are pregnant or breastfeeding; or you are of childbearing age and not using effective birth control. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICE3'-deoxy-3'-[18F]fluorothymidine

The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.

Locations(1)

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00935090

Related Trials

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT052379863 locations

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT0532019824 locations

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

NCT063031931 location

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

NCT0425631771 locations

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT0495389721 locations